July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Novel Contrast Sensitivity Test as a New Measure of Visual Function in Central Serous Chorioretinopathy
Author Affiliations & Notes
  • Anna Marmalidou
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Esther Lee Kim
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Rebecca Silverman
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Merina Thomas
    Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States
  • Ines Lains
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Alice Choi
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Ava K Bittner
    Nova Southeastern University, College of Optometry, Fort Lauderdale, Florida, United States
  • Leo A Kim
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Luis A Lesmes
    Adaptive Sensory Technology, Inc., San Diego, California, United States
  • David N. Zacks
    Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States
  • John B Miller
    Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Anna Marmalidou, None; Esther Kim, None; Rebecca Silverman, None; Merina Thomas, None; Ines Lains, Allergan (R); Alice Choi, None; Ava Bittner, Adaptive Sensory Technology, Inc. (F); Leo Kim, None; Luis Lesmes, Adaptive Sensory Technology, Inc. (E), Adaptive Sensory Technology, Inc. (P), Adaptive Sensory Technology, Inc. (I); David Zacks, None; John Miller, Allergan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3126. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Marmalidou, Esther Lee Kim, Rebecca Silverman, Merina Thomas, Ines Lains, Alice Choi, Ava K Bittner, Leo A Kim, Luis A Lesmes, David N. Zacks, John B Miller; A Novel Contrast Sensitivity Test as a New Measure of Visual Function in Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3126.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of computerized testing of contrast function in central serous chorioretinopathy (CSCR).

Methods : A multicenter, prospective, cohort study of 36 eyes of 18 patients with a history of CSCR. Patients were enrolled from September 2016 to November 2017 and met the following criteria: age 18 years or older, history of current or prior CSCR, non-visually significant cataracts, and no other ocular pathology. All patients underwent spectral domain optical coherence tomography (SD-OCT) and testing of the contrast sensitivity function (CSF) using the quick CSF (qCSF) algorithm implemented on the novel AST platform (Adaptive Sensory Technology, San Diego, CA). The contrast sensitivity function was broadly summarized by the area under the log contrast sensitivity function (AULCSF). Results were compared to an already acquired age-matched control group of 81 eyes via z-score: zAULCSF = (AULCSF-meanControl)/stdControl.

Results : Of the 36 included eyes, 22 had evidence of current or prior CSCR. Affected eyes had a statistically significant reduction in the AULCSF compared to controls (.94 vs 1.28, p=.005). Mean best-corrected visual acuity was logMAR 0.09 (~20/25) in unaffected eyes versus 0.25 (~20/35) in affected eyes. Unaffected eyes had a statistically significant reduction in the AULCSF compared to controls (1.08 vs 1.28, p=.005), but not relative to affected eyes (p=.13). Comparing our results to the age-matched controls, the median z-score for AULCSF was -1.07 ± 1.34 in affected eyes, compared with -.15 ± 1.6 in unaffected eyes (p=0.005).

Conclusions : Contrast sensitivity is significantly reduced in eyes affected by CSCR. The qCSF test provides a sensitive and efficient way to provide additional functional vision measures that may otherwise not be well quantified with current clinical measures.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×